Építés alatt – nem éles oldal
Belépés
Fut, nem toboroz3. fázis

Double blind, multicentric, randomized, placebo-controlled trial, evaluating the efficacy of 24-month of bezafibrate in primary sclerosing cholangitis with persistent cholestasis despite ursodeoxycholic acid therapy (BEZASCLER

A legfontosabb adatok

Ki végzi
Assistance Publique Hopitaux De Paris
Hol
Franciaország33 helyszín, 1 országbanVálassz országot a helyszínekhez
Állapot
Fut, nem toboroz
Fázis
3. fázis
Résztvevők
130 fő, tervezett
Kezdés
2021. ápr. 6.
Várható befejezés
2027. ápr. 6.
A vizsgálat típusa
Beavatkozással járó
A regiszteradat frissítve
2026. november 9.

Ki vehet részt

Életkor
18 év felett
Nem
Nők és férfiak
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 36 feltétel megnézéseKevesebb

Ki vehet részt

  • Males or females ≥ 18 and ≤ 75 years
  • Large duct PSC verified by retrograde, operative, percutaneous or magnetic resonance cholangiography (MRC) demonstrating intrahepatic and /or extrahepatic biliary duct changes consistent with PSC
  • Colonoscopy (already done or scheduled before randomization) within the last 5 years (or within 6 months if IBD is associated to PSC) with neither cancer nor all-grade dysplasia or endoscopy of the ileal reservoir (already done or scheduled before randomization) within the last 2 years in patients with ileo-anal anastomosis
  • ALP ≥ 1.5 ULN
  • Traitement par l'AUDC (13-23 mg/kg/j) depuis ≥ 6 mois avant l'inclusion (Arrondi à l’unité le plus proche, par exemple 12.5 mg/kg/j arrondi à 13 mg/kg/j)
  • Using contraceptive in women of childbearing potential. Women of childbearing potential, i.e. fertile, following menarche and until becoming post-menopaused unless permanently sterile, who are sexually active have to apply a highly effective method of birth control with a low failure rate (i.e. less than 1% per year) when used constantly and correctly
  • Affiliation to a social security system (AME excepted)
  • Signed informed consent

Ki nem vehet részt

  • Treatment with a fibrate within the last 3 months inclusion
  • Dosage change of treatment for associated IBD ≤3 months prior to inclusion
  • History of acute cholangitis in the last 3 months prior to inclusion or current acute cholangitis or suspected cholangiocarcinoma
  • Endoscopic treatment for bile duct stenosis ≤ 3 months prior to inclusion or planned within 3 months post randomization date
  • Prior liver transplantation
  • Current active IBD defined as either current use of systemic corticosteroid therapy > 10 mg/day or budesonide > 3 mg /day or immunosuppressive drugs (cyclosporine, tacrolimus, mycophenolate mofetil, mTor inhibitors, JAK inhibitors) or a partial Mayo score > 2 in patients with ulcerative colitis (UC), unclassed colitis or a Crohn’s Disease Activity Index (CDAI) > 150 in patients with Crohn’s disease (CD)
  • Current or history of colonic cancer or all-grade dysplasia described at the last colonoscopy (Patients with a history of colon cancer and treated by total colectomy without recurrence for at least 5 years are eligible)
  • Any other cause of liver damage ((positive test for HBV, HCV, or HIV, excessive alcohol consumption, hemochromatosis, Wilson's disease, α1-antitrypsin deficiency, celiac disease
  • History of or established or suspected hepatobiliary carcinoma
  • Current or recent history (within 2 years) of clinically detectable Ascites or digestive hemorrhage
  • History of malignancy diagnosed or treated within 2 years (recent localized treatment of squamous or non-invasive basal skin cancers is permitted; cervical carcinoma in situ is allowed if appropriately treated prior to Screening)
  • Known hypersensitivity to bezafibrate, any of the components of Befizal© or other fibrates
  • Current or recent history (within 2 years) of Autoimmune hepatitis defined by the presence of interface hepatitis documented on liver biopsy and at least 1 of the 2 following criteria: 1) AST or ALT > 5 ULN, 2) Positive anti smooth muscle auto antibodies or serum IgG > 1.5 ULN
  • Secondary causes of sclerosing cholangitis including IgG4-associated cholangitis (elevated serum IgG4 > 4 ULN)
  • Patient with congenital galactosemia, glucose malabsorption, or lactase deficiency because of presence of lactose in 400 mg SR tablets of bezafibrate and in placebo tablets
  • Renal insufficiency (clearance < 60 ml/min or serum creatinine level > 130 μmole/L)
  • Total bilirubin in the last 3 months > 50 μmole/L (3 mg/dl)
  • Gilbert syndrome defined as unconjugated bilirubinemia > LSN in the last 3 months (according to the laboratory reference value)
  • Albumin in the last 3 months < LLN (according to the laboratory reference value)
  • Platelets count in the last 3 months < 100000/mm3
  • ALT or AST > 5 ULN in the last 3 months
  • Child-Pugh score B or C
  • Any severe comorbidity that may reduce life expectancy
  • Known photosensitivity or photoallergy reactions to fibrate
  • Pregnancy (or desire for)
  • Breastfeeding
  • Participation in any other interventional study or in the exclusion period any other interventional study
  • Prothrombin index in the last 3 months < 70%

Hol van ez a vizsgálat?

Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.

A vizsgálatról

Mit akar kideríteni a vizsgálat

To assess the efficacy of 24-month treatment with bezafibrate (400 mg SR/d) versus placebo in addition to standard UDCA therapy in primary sclerosing cholangitis

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on és az EU hivatalos vizsgálati nyilvántartásában (CTIS).
Hivatalos cím
Double blind, multicentric, randomized, placebo-controlled trial, evaluating the efficacy of 24-month of bezafibrate in primary sclerosing cholangitis with persistent cholestasis despite ursodeoxycholic acid therapy (BEZASCLER)
A regiszteradat frissítve
2026. november 9.